JAKARTA - To suppress the spread of the COVID-19 pandemic, the government ensures that the people will receive cheap therapeutic drugs for the prevention and cure of the SAR Cov-2 virus.

The acceleration of clinical trials conducted by the Food and Drug Supervisory Agency (BPOM) on Ivermectin as a preventive therapy drug and healing for COVID-19 patients will be the new game-changer so that Indonesia can control this pandemic.

This was emphasized by the Minister of State-Owned Enterprises, Erick Thohir in response to the BPOM's move which was conducting clinical trials of Ivermectin as a therapeutic drug for COVID-19 patients. Preparations have also been made by PT Indofarma Tbk to mass-produce Ivermectin so that when the clinical trials are completed and the distribution permit has been issued by BPOM, the drug is ready to be mass-produced in a short time.

"In terms of infrastructure, we are ready to mass-produce Ivermectin. This drug will become a cheap therapeutic drug for the people, especially Indofarma has prepared production of 4.5 million tablets per month. Ivermectin turns out to be good for all of us, so we will boost this production to quickly reduce the positive cases of COVID-19", said Minister Erick Thohir in Jakarta, Monday, June 28.

The provision of cheap COVID-19 therapeutic drugs is indeed the main concern of Minister Erick Thohir. So people who prioritize basic needs in the midst of this pandemic are no longer burdened with expensive drug prices.

According to the plan, the price of therapeutic drug Ivermectin will be priced between IDR 5,000 to IDR 7,000 per tablet.

"With cheap and affordable drug prices, I'm sure people will be able to get them easily and won't be a burden. Especially for the prevention of COVID-19, it doesn't need to always be consumed, but only 2-3 tablets. Likewise for healing. to make our people healthy and Indonesia free from this pandemic, it will be realized soon", said Erick.


The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)